Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest. Elan said that
Synta is currently enrolling patients in a Phase 2 single-arm, open-label, single-agent study of STA-9090 in patients with stage IIIB or IV non-small cell lung cancer, with patient
The ‘GreenVax Project’ will demonstrate evidence of concept for a large-scale facility producing vaccine using Nicotiana plants grown hydroponically in a contained environment. iBio claimed that its green
Both agencies have consented to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the US and the
Enzon said that the study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies
A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avastin. Data from the study will be submitted for presentation at the American Society
Reportedly, Kyowa Hakko Kirin has confirmed KW-2246’s safety and efficacy in clinical trials conducted in Japan. The drug will be marketed by Kyowa Hakko Kirin and Hisamitsu Pharmaceutical.
The drug discovery expertise includes fragment screening, structural biology and protein crystallography, to discover and profile novel compounds against additional antibacterial targets selected by Cubist. Evotec and Cubist
The new drug application 22-299 provides for the use of Nevirapine tablets for oral suspension 50mg in combination with other antiretrovirals and its indicated for the treatment of
Dynavax also said that the trial will be conducted at centers that are members of the Vaccine Testing and Evaluation Units (VTEUs) of the National Institute for Allergy
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.